Effectiveness and safety of once‐weekly subcutaneous semaglutide versus other glucose‐lowering agents in real‐world patients with type 2 diabetes: A retrospective, observational post‐marketing study

Documents similaires

• Impact of baseline characteristics on the efficacy of once‐weekly subcutaneous semaglutide among participants with type 2 diabetes : A post hoc analysis of SUSTAIN China
  par: Linong Ji, et autres
  Publié: (2024)
• Cost‐utility analysis and drug pricing for tirzepatide for type 2 diabetes in the Chinese market compared with semaglutide
  par: Shanshan Hu, et autres
  Publié: (2024)
• Real‐world safety profile of once‐weekly semaglutide in people with type 2 diabetes: Analysis of pooled data from the SemaglUtide Real‐world Evidence (SURE) programme
  par: Jean‐François Yale, et autres
  Publié: (2024)
• Efficacy and safety of once‐weekly subcutaneous semaglutide 2.4 mg for the management of overweight or obesity in Asian populations: A systematic review, meta‐analysis and meta‐regression of randomised trials
  par: Hendra Zufry, et autres
  Publié: (2025)
• Cost‐utility of once‐weekly insulin icodec versus once‐daily basal insulins for type 2 diabetes in China
  par: Xichen Tong, et autres
  Publié: (2026)